六月 2026
- Home
- Haematologic Technologies
六月 2026的Haematologic Technologies市场份额分析
prolytix, formerly haematologic technologies, provides full bioanalysis and protein chemistry services, research reagents, and collection devices.
Haematologic Technologies(包含公司地区分支机构)
查看更多网站流量和参与度信息- haemtech.com
Haematologic Technologies收入截至 六月 2026为 10M - 15M
Haematologic Technologies主要域名产生的收入
3 年中Haematologic Technologies主要域名的收入
Haematologic Technologies主要域名的收入
Haematologic Technologies热门域名的总访问量
了解Haematologic Technologies市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
无数据可显示
无数据可显示
Haematologic Technologies热门域名的平均访问时长
分析Haematologic Technologies参与度指标。
过去 3 个月的平均访问时长
无数据可显示
无数据可显示
Haematologic Technologies热门域名的平均页面浏览量
了解Haematologic Technologies如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
无数据可显示
无数据可显示
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Haematologic Technologies 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Haematologic Technologies, Inc. hired Joe Flynn as Chief Commercial Officer on Jan 6th '22.Haematologic Technologies ("HT"), a global leader in large molecule analytical services and plasma reagents, today announced the appointment of Joe Flynn as Chief Commercial Officer.
一月 6, 2022阅读更多
新闻Haematologic Technologies, Inc. hired John Strokis as Vice President, Quality on Dec 16th '21.Haematologic Technologies ("HT"), a global leader in large molecule bioanalysis and biologic reagents, today announced the appointment of John Strokis as Vice President, Quality.
十二月 16, 2021阅读更多
新闻Haematologic Technologies, Inc. launched High Resolution Mass Spectrometry on Oct 1st '20.Haematologic Technologies (HTI), a leading protein chemistry company providing products and analytical services supporting the research, development, and commercialization of large molecule biotherapeutics, today announced the addition of a High Resolution Mass Spectrometry (HRMS) lab headed by Kevin Van Cott, PhD, a global expert in the use of HRMS for Host Cell Proteins (HCP) and biotherapeutics characterization.
十月 2, 2020阅读更多
查看 Haematologic Technologies 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
